BridgeBio Faces Earnings with Two Activists Trimming and Analysts Debating the Target

BridgeBio Pharma is less shorted than its peer group heading into today's print, with short interest at 10.6% of the free float, while correlated names like NGNE surged 16.6% on the week and the peer median moved 4.3% against BBIO's 3.8% gain.

The short position itself has been in steady retreat. From roughly 21.8 million shares in late September, it has fallen to 20.3 million, down about 6% over the month. Borrow costs are low at 0.55%, and availability is extremely loose at 838%: for every share already lent out, more than eight remain available. That profile describes a short base winding down rather than building, and with days-to-cover at 7.7 on official FINRA data, there is no squeeze pressure to speak of. Options traders are leaning the same way: the put/call ratio is 0.23, below its 20-day average of 0.24, with call volume dominant and the reading near the low end of the past year's range.

The analyst community has been more active and more divided. The consensus remains a buy, but targets have been moving in opposite directions. Morgan Stanley lowered its target to $87 from $97 last week while keeping its Overweight rating. Piper Sandler went the other way, raising to $120. UBS assumed coverage at Buy with a $92 target. The spread between the most bullish price target on the register ($156, Barclays) and the stock's current price of $70.73 is wide, but so is the internal disagreement: the Street is aligned on direction but not on magnitude. The bull case rests on Attruby's acceleration, with US sales of $222 million in Q2 growing 23% quarter-on-quarter and 211% year-on-year in a TTR-CM market the company says expanded 51% annually. The bear case is the balance sheet: $1.9 billion of debt, $450 million maturing in 2029, and cash that fell from $940 million to $720 million in a single quarter. Those two facts, a fast-growing drug and a leveraged structure, are what the market has to weigh.

The ownership picture adds another layer. Two Schedule 13D activists are on the register, and both have been trimming. Viking Global Investors reduced its stake from 6.1% to 5.0% as last disclosed in July, while KKR cut from 7.0% to 4.7% as of August. KKR's filing last reported below the 5% threshold, meaning further reductions may not trigger a new disclosure. As always with 13D/G positions, stakes are as-last-disclosed and a holder dropping below 5% can exit without a further filing. CEO Neil Kumar's own sales over August and September, all under a pre-arranged 10b5-1 plan, totalled roughly $2.7 million, a mechanical selling programme rather than a discretionary signal.

Medicaid reimbursement data from the Centers for Medicare and Medicaid Services shows Attruby dollars and units reimbursed have risen for three consecutive quarters, the most recent period ending January 2026. Neither that dataset nor the drug trials data from the US National Library of Medicine has been measured to lead BridgeBio's reported figures, so they provide context on the drug's Medicaid footprint rather than a read on today's print.

Today's report will test whether Attruby's commercial momentum is outpacing the cost of carrying that debt load, and whether the pipeline assets justify a valuation that the activist holders have been quietly reducing their exposure to.